UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) Delaware 22-3550230 (State or other jurisdiction of inco ...

NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 Increased full-year 2024 revenue guidance to $76 million to $78 million Demonstrated continued operating discipline as evidenced by further decrease in cash burn Management scheduled to host a conference call today at 4:30 p.m. ET Mountain View, Calif. – August 13, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transform ...

NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Vik Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Michael Polark - Wolfe Research Drew Ranieri - Morgan Stanley Operator Good afternoon and welcome to NeuroPace's F ...

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Jeremy Feffer – Managing Director, LifeSci Advisors Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Vik Chopra – Wells Fargo Mike Kratky – Leerink Partners Michael Polark – Wolfe Research Drew Ranieri – Morgan Stanley Operator Good afternoon, and welcome to NeuroPace’s Fourth Quarter and Year-End 20 ...

nuvei MARCH 5, 2024 Fourth Quarter 2023 Financial Snapshot Q4 2023 | 1 | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------|--------------------------------------------------------------|---------------------|--------------------------------------------|--------------------------------------------------------------------------|--------------|--------------------------------------------------------|---------------------| | Total Volume(1) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ___________ Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) Delaware 22-3550230 (State or Other Jurisd ...

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Michael Polark - Wolfe Research Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, greetings and welcome to the NeuroPace, Inc. Third Quarter 2023 Earnings Conference Call. [Oper ...

Investor Presentation November 2023 1 Disclaimer In addition to background and historical information, this presentation contains "forward-looking statements" based on NeuroPace's current expectations, estimates, forecasts and beliefs, including financial results for the third quarter ended September 30, 2023, information about NeuroPace's market opportunity, growth drivers and market penetration, commercial strategy, future pipeline, estimates of market opportunity and forecasts of market and revenue growt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) Delaware 22-3550230 (State or other jurisdiction of ...

NeuroPace, Inc. (NASDAQ:NPCE) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Paige Chamberlain - Wolfe Research Operator Good afternoon and welcome to NeuroPace's Second Quarter 2023 Earnings Conference Call. As a reminder, this conference is being recorded. I ...